Evidence for a Multivalent Interaction of Symmetrical, N-Linked, Lidocaine Dimers with Voltage-Gated Na⁺ Channels


Theravance Inc., South San Francisco, California

Received September 23, 2005; accepted December 9, 2005

ABSTRACT

The interaction of symmetrical lidocaine dimers with voltage-gated Na⁺ channels (VGSCs) was examined using a FLIPR membrane potential assay and voltage-clamp. The dimers, in which the tertiary amines of the lidocaine moieties are linked by an alkylene chain (two to six methylene units), inhibited VGSC activator-evoked depolarization of cells heterologously-expressing rat (r) Na₁,1.2a, human (h) Na₁,1.5, and rNa₁,1.8, with potencies 10- to 100-fold higher than lidocaine (compound 1). The rank order of potency (C₄ (compound 4) > C₃ (compound 3) ≥ C₂ (compound 2) = C₀ (compound 5) = C₆ (compound 6) >> compound 1) was similar at each VGSC. Compound 4 exhibited strong use-dependent inhibition of hNa₁,1.5 with pIC₅₀ values <4.5 and 6.0 for tonic and phasic block, respectively. Coincubation with local anesthetics but not tetrodotoxin attenuated compound 4-mediated inhibition of hNa₁,1.5. These data suggest that the compound 4 binding site(s) is identical, or allosterically coupled, to the local anesthetic receptor. The dissociation rate of the dimers from hNa₁,1.5 was dependent upon the linker length, with a rank order of compound 1 >> compound 5 = compound 6 >> compound 2 >> compound 3. The observation that both the potency and dissociation rate of the dimers was dependent upon linker length is consistent with a multivalent interaction at VGSCs. hNa₁,1.5 VGSCs did not recover from inhibition by compound 4. However, “chase” with free local anesthetic site inhibitors increased the rate of dissociation of compound 4. Together, these data support the hypothesis that compound 4 simultaneously occupies two binding sites on VGSCs, both of which can be bound by known local anesthetic site inhibitors.

VGSCs are transmembrane protein complexes that increase Na⁺ permeability in response to membrane depolarization. Mammalian VGSCs consist of a pore-forming or α subunit, which is sufficient for functional channel expression, associated with one or more auxiliary β subunits. The α subunit consists of four homologous domains (D1–D4), each of which has six transmembrane a helices (S1–S6) (Catterall, 2000). The VGSC is thought to be organized as a pseudotetramer with the S6 segments lining the inner surface of the channel pore (Sato et al., 2001). At least nine genes encoding VGSC α subunits have been identified (Na₁,1.1–Na₁,1.9), which can be differentiated based on their tissue distribution profiles and biophysical and/or pharmacological properties (Goldin et al., 2000).

In the plasma membrane, VGSCs interconvert between multiple conformational states (e.g., closed/resting, open, inactivated) in response to changes in membrane potential (Hille, 2001). The affinity of local anesthetics, which confer their activity by inhibiting the conduction of Na⁺ ions through VGSCs and, thereby, action potential initiation/propagation in excitable tissues, depends upon the conformational state of the channel (Ragsdale et al., 1991). Local anesthetics bind to nonresting (i.e., open/inactivated states) with higher affinity than to resting states (Hondeghem and Katzung, 1977; Bean et al., 1983). The higher affinity of local anesthetics for the nonresting states is manifested as use dependence.

Receptors, ion channels, and enzymes that possess multiple binding sites due to symmetry, pseudosymmetry, or the presence of unrelated auxiliary sites may be targeted pharmacologically with dimeric ligands. Such an approach seeks to tether two ligands with a linker that can orient the ligands to bind the target simultaneously (Kiessling et al., 2000; Wright and Usher, 2001). The simultaneous occupation of two distinct concavities on a protein by such a bivalent ligand can confer upon it enhanced affinity, duration of action, and/or subtype selectivity relative to its component monomeric ligand(s) (Mammen et al., 1998). The critical parameters that control these properties are linker length, linker...
Bivalent ligand design has been used successfully for such G-protein-coupled receptors as β-adrenergic (Kizuka and Hanson, 1987), k opioid (Portoghese et al., 1988), muscarinic acetylcholine (Christopoulos et al., 2001), 5-HT₁AR (LeBoullec et al., 1995) and 5-HT₁BRD (Halazy et al., 1996) receptors. Similar studies have also been undertaken for voltage-gated calcium channels (Joslyn et al., 1988) and SKCa channels. Similar studies have also been undertaken for voltage-gated calcium channels (Joslyn et al., 1988) and SKCa channels.

To the best of our knowledge, this approach has not been applied previously to VGSCs, although a number of structural features of VGSCs are consistent with the application of multivalent ligand design. In addition to the putative tetrameric organization of their four homologous domains, VGSCs also have six distinct binding sites for small molecules and peptide toxins (Cestele and Catterall, 2000). Based on the results of site-directed mutagenesis studies, it has been proposed that the S6 segments contribute to a domain-interface binding site for local anesthetics, analogous to that for antagonist binding in L-type Ca²⁺ channels (Hockerman et al., 1997). Thus, amino acid residues in D1–S6 (Nau et al., 1999; Yarov-Yarovoy et al., 2002), D3–S6 (Wang et al., 2000; Yarov-Yarovoy et al., 2001), and D4–S6 (Ragsdale et al., 1996) have been proposed to participate in local anesthetic binding. However, other groups (Bennett et al., 1995; Kuroda et al., 1996, 2000) have proposed that, in addition to the D4–S6 conserved local anesthetic receptor, lidocaine also interacts with the D3–D4 cytoplasmic linker, which forms part of the inactivation domain. Furthermore, the existence of two independent binding sites for local anesthetics or small molecule VGSC inhibitors has been postulated (Lee-Son et al., 1992; Mujtaba et al., 2001, 2002; Leuwer et al., 2004).

In the present study, we examined the interaction of a series of symmetrical, N-linked lidocaine dimers, in which the nitrogens of each lidocaine moiety are tethered by an unsubstituted alkylene linker (two to six methylene units) (Fig. 1), with tetrodotoxin-sensitive (Nav1.2a), tetrodotoxin-unsubstituted alkylene chain (two to six methylene units) and then for 4 min after the addition. For rNav1.8-F-11, all additions were coincubated with 300 nM tetrodotoxin (final assay concentration) before activator addition. F-11 cells express an endogenous tetrodotoxin-resistant VGSC subtypes. Therefore, recombinant rNaVa, 1.8-F-11 cells were concomitantly used with native tetrodotoxin-resistant VGSCs, primary cultures of rat dorsal root ganglia neurons were used.

**Materials and Methods**

**Cell Culture of rNaV1.2a-CHO, hNaV1.5-293-EBNA, and rNaV1.8-F-11 Cells.** rNaV1.2a-CHO cells were obtained under license from Dr. W. Catterall (University of Washington, Seattle, WA) and grown in RPMI 1640 medium containing 1 mM l-glutamate, supplemented with 5% heat-inactivated fetal bovine serum, 200 μg/ml G-418 (Geneticin) and 50 units/ml penicillin/50 μg/ml streptomycin. hNaV1.5-293-EBNA cells were obtained under license from Dr. A. O. Grant (Duke University, Chapel Hill, NC) and grown in Dulbecco's modified Eagle's medium containing l-glutamate, supplemented with 5% heat-inactivated fetal bovine serum, 50 μg/ml hygromycin, an additional 1 mM l-glutamate, and 50 units/ml penicillin/50 μg/ml streptomycin.

F-11 cells were obtained under license from Dr. M. Fishman (Harvard Medical School, Cambridge, MA). Untransfected F-11 and rNaV1.8-F-11 cells were grown in Ham's F12 medium containing l-glutamate supplemented with 20% heat-inactivated fetal bovine serum, 1% hypoxanthine/aminopterin/thymidine (100 μM hypoxanthine, 0.4 μM aminopterin, and 16 μM thymidine), additional 1 mM l-glutamate and 50 units/ml penicillin/50 μg/ml streptomycin, in the absence and presence of 200 μg/ml geneticin (G-418), respectively. All cell lines were grown routinely as monolayers in an atmosphere of 95% O₂/5% CO₂ at 37°C.

For FLIPR studies, cells were seeded into black-walled, clear-bottomed, 96-well microtiter plates coated with poly-D-lysine (BD, Franklin Lakes, NJ), rNaV1.2a-CHO and hNaV1.5-293-EBNA cells were seeded at optimized concentrations of 50 × 10⁶ cells/well and 20 × 10⁶ cells/well, respectively and used for assay approximately 3 h later. rNaV1.8-F-11 cells were plated at an optimized concentration of 20 × 10⁶ cells/well and incubated overnight before assay. For electrophysiological studies cells were plated onto poly-D-lysine–coated (100 μg/ml) glass coverslips at a density that enabled isolated cells to be selected for voltage-clamp recordings and maintained under 95%/5% O₂/CO₂ at 37°C for 12 to 48 h before recording.

**Measurement of Membrane Potential Using the FLIPR.** Membrane potential in rNaV1.2a-CHO, hNaV1.5-293-EBNA, and rNaV1.8-F-11 cell lines was measured using a fluorescent membrane potential-sensitive (FMP) dye (Molecular Devices, Sunnyvale, CA) and FLIPR as described previously by Vickery et al. (2004). Membrane depolarization, or hyperpolarization, of FMP dye-loaded cells produces an increase, or decrease, respectively, in fluorescence emission.

In brief, cells were incubated with FMP dye under the conditions indicated in parentheses: rNaV1.2a-CHO (50 min, 22°C), hNaV1.5-293-EBNA (35 min, 22°C), and rNaV1.8-F-11 (45 min, 37°C). For the final 30 min of the dye loading period, cells were incubated in the absence (i.e., control) or presence of increasing concentrations of antagonists. The plates were then placed on the FLIPR and cell fluorescence monitored (λₐ, 488 nm; λₑ, relevant emission filter provided by Molecular Devices) before and after the addition of Hanks' balanced salt solution-HEPES buffer containing the appropriate concentrations of VGSC activators. Activation of Na⁺ channels in rNaV1.2a-CHO, hNaV1.5-293-EBNA, and rNaV1.8-F-11 cells was achieved using veratridine (20 μM) alone, veratridine (20 μM) plus diltiazem (3 μM), and veratridine (20 μM) plus diltiazem (20 μM), respectively. Fluorescence emission was monitored for 15 s before the addition of stimulus buffer to establish a baseline and then for 4 min after the addition. For rNaV1.8-F-11, all additions of Na⁺ channel activators were made at 37°C on the FLIPR. To ensure that the temperature was stable during the recording period, rNaV1.8-F-11 cells were pre-equilibrated for 15 min in the FLIPR before activator addition. F-11 cells express an endogenous tetrodotoxin-sensitive VGSC; therefore, recombinant rNaV1.8-F-11 cells were concomitantly used with native tetrodotoxin-resistant VGSCs, primary cultures of rat dorsal root ganglia neurons were used.

**Fig. 1. Structures of lidocaine (compound 1), symmetrical, N-linked lidocaine dimers, tethered by an unsubstituted alkylene linker (n = 2 to 6 methylene units; compounds 2-6) and three control molecules (compounds 7, 8, and 9).**
tion after activator addition) to isolate rNa,1.8-mediated depolarizations. A panel of control compounds, including tetrodotoxin, lidoca-aine, bupivacaine, and mexiletine, was included in all experiments to confirm the stability of VGSC expression in the respective cell lines.

Stock solutions (10 mM) of all compounds were prepared in 100% dimethyl sulfoxide, except for veratridine and deltamethrin, for which a 40 μM veratridine stock solution in 100% EtOH and 80 μM deltamethrin stock solution in 100% dimethyl sulfoxide were prepared.

FLIPR FMP Assay Data Analysis. FLIPR data points were taken every 2 s. For data analysis, peak fluorescence (fluorescence intensity units) was measured using the FLIPR software. Peak values were exported into Microsoft Excel and then into Prism 3.0 (GraphPad Software, San Diego, CA). Concentration-response curves were fitted to a four-parameter sigmoidal function, with a variable slope, using Prism. Data were analyzed with the assumption that a single dimer molecule bound to, and blocked, one VGSC. One-way ANOVA and post hoc Tukey’s multiple comparison tests were conducted using Prism. Data represent mean ± S.D. of at least three independent experiments. All experiments were conducted at least in duplicate.

Preparation of Neonatal Rat Dorsal Root Ganglia Primary Cultures. Sprague-Dawley rats 1 or 2 days old were sacrificed by CO2 inhalation, in accordance with the Institutional Animal Care & Use Committee regulations, and dorsal root ganglia from all spinal levels were dissected. Primary cultures of neonatal rat dorsal root ganglia cells were prepared according to a modification of the procedure described previously (Vickery et al., 2004). In brief, dorsal root ganglia were dispersed using a combination of enzymatic treatments and mechanical trituration. Dorsal root ganglia were incubated with collagenase (0.06%, 25 min at 37°C) and then trypsin (0.125%, 15 min at 37°C) before trituration with fire-polished glass Pasteur pipettes in the presence of 0.01% DNase. The final cell suspension was resuspended in Dulbecco’s modified Eagle’s/Ham’s F12 medium containing 10% fetal bovine serum, 100 ng/ml NFG, and 10 μM arabi- noside C (to suppress the growth of non-neuronal cells) and plated onto 13-mm glass coverslips coated with poly-D-lysine (10 μg/ml) and laminin (5 μg/ml) at a density that enabled isolated cells to be selected for voltage-clamp recordings. Cells were maintained at 37°C in an atmosphere of 95%/5% O2/CO2 for 1 to 2 days.

Whole-Cell Voltage-Clamp. Patch pipettes were manufactured from glass capillary tubing (borosilicate thin wall; o.d., 1.5 mm; i.d., 1.17 mm; Warner Instruments Corporation, Hamden, CT) using a P-97 Flaming-Brown pipette puller (Sutter Instrument Co., Novato, CA) and polished with a microforge (Narishige, East Meadow, NY). The measured pipette resistance was between 1 and 3 MΩ.

Materials. The following drugs were obtained from the commercial sources indicated in parentheses: tetrodotoxin (Hyclone, Logan, UT) and FMP (Molecular Devices). All other reagents were obtained from Sigma-Aldrich (St. Louis, MO).

For rat dorsal root ganglia tetrodotoxin-resistant Na+ currents, in the absence of compound, there was a 23 ± 2% (mean ± S.E.M., n = 6 cells) reduction in the magnitude of the final pulse in the 5-Hz train at the high stimulus frequency. To correct for this decrement in current amplitude, which occurs in the absence of drug, each nor- malized data value in the presence of drug was divided by that in the absence of drug.

Concentration-response curves of normalized current amplitude against compound concentrations were constructed (n = 3 or more cells for each point), and the data were fitted to a four-parameter sigmoidal function using Origin (OriginLab Corp., Northampton, MA). The upper and lower asymptotes were constrained to 1 and 0, respectively.

Compound dissociation rates from hNa,1.5 and rNa,1.2a VGSCs were determined. After stabilization of the voltage clamp, Na+ cur- rent magnitude was monitored, at a frequency of 0.2 Hz, for a period of 1 min. hNa,1.5–293-EBNA or rNa,1.2a-CHO cells then were exposed to the specified concentration of lidocaine or dimer according to the protocols described above. At the end of the 5-Hz stimulus train, the compound was washed out by continuous perfusion with extra- cellular buffer and current magnitude monitored at a frequency of 0.2 Hz for an additional 10 min. Current amplitudes were nor- malized to the initial current in the absence of compound and plots of normalized current amplitude against time constructed (n = 3 or more cells for each point). Data (from time of compound washout) were fitted to a single exponential decay function using Origin software.

Unpaired t test or one-way ANOVA and post hoc Dunnett’s test were conducted using GraphPad Prism. Data represent mean ± S.D. for at least three cells.

Materials. Cell culture media and supplements were obtained from Invitrogen (Carlsbad, CA). The following materials were ob- tained from the sources indicated in parentheses: fetal bovine serum (HyClone, Logan, UT) and FMP (Molecular Devices). All other re- agents were obtained from Sigma-Aldrich (St. Louis, MO).

The following drugs were obtained from the commercial sources indicated in parentheses: deltamethrin (RU29974; Dr. Ehrenstorfer GmbH, Augsburg, Germany); veratridine, tetrodotoxin (Sigma- Aldrich); mexiletine, pimozone, bupivacaine, 4030W9, lamotrigine, compound 1 [lidocaine; 2-diethylaminomethyl-2-(2,6-dimethyl-phenyl)-acetamide], compound 2 [N-(2,6-dimethyl-phenyl)-2-[(2,6-dimethyl-phenylcarbamoyl)methyl]-methyl-amino-ethyl]-methyl-aminomethyl-acetamide], compound 3 [N-(2,6-dimethyl-phenyl)-2-[(2,6-dimethyl-phenylcarbamoyl)methyl]-methyl-aminomethyl-propyl]-methyl-aminomethyl-acetamide], compound 4 [THX-170148; N-(2,6-dimethyl-phenyl)-2-[(4,6,6-tri-methyl-phenylcarbamoyl)methyl]-methyl-aminomethyl-butyl]-methyl-aminomethyl-acetamide], compound 5 [N-(2,6-
Results

Inhibition of Na⁺ Channel Activator-Evoked Depolarization of rNav1.2a-CHO, hNav1.5–293-EBNA, and rNav1.8-F-11 Cells by Lidocaine Dimers Is Dependent upon the Length of the Tether. The interaction of the dimers with specific VGSC subtypes initially was examined using rNav1.2a-CHO, hNav1.5–293-EBNA, and rNav1.8-F-11 recombinant cell lines and a novel FLIPR membrane potential sensitive dye assay (Vickory et al., 2004). Tetrodotoxin produced a concentration-dependent inhibition of Na⁺ channel activator-evoked depolarization of rNav1.2a-CHO, hNav1.5–293-EBNA, and rNav1.8-F-11 cells with pIC₅₀ values as expected for inhibition of Na⁺, Na₀.1, hNav1.5, and Na₀.1ₘ Na⁺ channels, respectively (Table 1). Lidocaine, and the dimers, also produced a concentration-dependent inhibition of activator-evoked depolarization in each cell type (Table 1). The potencies of the dimers were dependent upon the length of the linker and ranged from 10 to >100-fold higher than that of lidocaine (p < 0.001; Tukey’s test) (Fig. 2). The rank order of potencies was similar at rNav1.2a (compound 4 > compound 3 > compound 6 = compound 5 = compound 2 >> lidocaine), hNav1.5 (compound 4 > compound 3 = compound 6 = compound 5 = compound 2 >> lidocaine), and rNav1.8 (compound 4 > compound 3 > compound 6 = compound 5 = compound 2 >> lidocaine) VGSC subtypes. There were statistically significant differences between the potencies of each dimer for the three respective VGSC subtypes (one-way ANOVA, p < 0.05); however, these were small (<10-fold).

Thus, lidocaine and compound 2 were significantly less potent at rNav1.2a than at both hNav1.5 and rNav1.8 subtypes, whereas compounds 5 and 6 were significantly less potent at rNav1.2a than at hNav1.5 (p < 0.05, Tukey’s test). Compounds 3 and 4 were significantly less potent at both rNav1.2a and hNav1.5 subtypes than rNav1.8 (p < 0.05, Tukey’s test). Under the present experimental conditions, the values for the Hill coefficients for the lidocaine dimers were, in general, greater than 1.0 at all VGSC subtypes. However, there were no consistent differences between the Hill slopes for the dimers and lidocaine.

To probe the specificity of the interaction of the most potent dimer, compound 4, with VGSCs, the effects of three control compounds (compounds 7, 8, and 9) (Fig. 1) were examined. These compounds make up a single lidocaine moiety coupled to a C₆ linker where the second lidocaine moiety has been replaced by one of three functional groups, corresponding to critical components of the local anesthetic pharmacophore, specifically an amine (positively-charged nitrogen), an amide, and an arene group (Rang and Dale, 1991). Compound 7 had no effect on Na⁺ channel activator-evoked depolarization up to a concentration of 100 μM, the highest concentration tested (Table 1). In contrast, compounds 8 and 9 both inhibited activator-evoked depolarization, but were at least 1 order of magnitude less potent than compound 4 itself at the respective VGSC subtypes (p < 0.001, Tukey’s test) (Table 1).

Lidocaine Dimers Are Potent, Strongly Use-Dependent Inhibitors of rNav1.2a, hNav1.5, and Rat Dorsal Root Ganglia Tetrodotoxin-Resistant VGSCs. The inhibitory activities of a library oflidocaine dimers are shown in Fig. 2. The effects of compounds 2 to 6 on Na⁺ channel activator-evoked depolarization of rNav1.2a-CHO (●), hNav1.5–293-EBNA (■), and rNav1.8-F-11 (▲) cells. FMP dye-loaded cells were incubated for 30 min in the absence or presence of antagonist. Membrane potential in rNav1.2a, hNav1.5, and rNav1.8 cells then was monitored using a FLIPR before and after the addition of veratridine (20 μM), veratridine (20 μM) plus deltamethrin (3 μM), or veratridine (20 μM) plus deltamethrin (20 μM), respectively, to elicit membrane depolarization. Data represents mean ± S.D. of 4 to 26 independent pIC₅₀ determinations, each performed in duplicate. ++, p < 0.001, +, p < 0.01, •, p < 0.05, significantly different from rNav1.8; ††, p < 0.01, †, p < 0.05, significantly different from hNav1.5; and ‡‡, p < 0.01, significantly different from both hNav1.5 and rNav1.8 (Tukey’s multiple comparison test).

TABLE 1

| pIC₅₀ values for lidocaine and lidocaine dimers at rNav1.2a, hNav1.5, and rNav1.8 recombinant VGSCs determined using FLIPR membrane potential assay
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>rNav1.2a</td>
<td></td>
<td>hNav1.5</td>
<td></td>
</tr>
<tr>
<td>rNav1.2a</td>
<td>pIC₅₀</td>
<td>hNav1.5</td>
<td>pIC₅₀</td>
<td>rNav1.8</td>
</tr>
<tr>
<td>Compound 2</td>
<td>4.7 ± 0.2</td>
<td>5.7 ± 0.1</td>
<td>5.4 ± 0.2</td>
<td>5.2 ± 0.2</td>
</tr>
<tr>
<td>Compound 3</td>
<td>5.4 ± 0.5</td>
<td>5.3 ± 0.3</td>
<td>5.5 ± 0.4</td>
<td>6.0 ± 0.4</td>
</tr>
<tr>
<td>Compound 4</td>
<td>6.0 ± 0.4</td>
<td>6.2 ± 0.2</td>
<td>6.2 ± 0.2</td>
<td>6.8 ± 0.4</td>
</tr>
<tr>
<td>Compound 5</td>
<td>5.2 ± 0.2</td>
<td>5.4 ± 0.3</td>
<td>5.5 ± 0.1</td>
<td>6.8 ± 0.4</td>
</tr>
<tr>
<td>Compound 6</td>
<td>5.0 ± 0.2</td>
<td>5.6 ± 0.2</td>
<td>5.5 ± 0.1</td>
<td>5.6 ± 0.2</td>
</tr>
<tr>
<td>Compound 7</td>
<td>5.0 ± 0.3</td>
<td>4.9 ± 0.2</td>
<td>4.7 ± 0.4</td>
<td>&lt;4</td>
</tr>
<tr>
<td>Compound 8</td>
<td>5.0 ± 0.2</td>
<td>4.7 ± 0.4</td>
<td>4.7 ± 0.4</td>
<td>&lt;4</td>
</tr>
<tr>
<td>Compound 9</td>
<td>5.0 ± 0.2</td>
<td>4.2 ± 0.2</td>
<td>4.2 ± 0.2</td>
<td>&lt;4</td>
</tr>
<tr>
<td>Tetrodotoxin</td>
<td>8.7 ± 0.2</td>
<td>9.2 ± 0.2</td>
<td>9.2 ± 0.2</td>
<td>9.2 ± 0.2</td>
</tr>
</tbody>
</table>

Data represents mean ± S.D. of number of observations (n) indicated.
hibitory properties of the dimers at rNav1.2a, hNav1.5, and rat DRG tetrodotoxin-resistant VGSCs were examined using whole cell voltage-clamp techniques.

The characteristics of hNav1.5 Na$^+$ current block by lidocaine (300 μM) and the most potent dimer, compound 4 (3 μM) are illustrated by the representative raw current traces in Fig. 3, a and c, insets. Lidocaine (300 μM) inhibited the first and last pulses in the 5-Hz train by 53 ± 0.3% (tonic inhibition) and 84 ± 0.9% (phasic inhibition) (n = 3 cells), respectively. In contrast, for compound 4 (3 μM), there was minimal (15 ± 8%) tonic inhibition but 80 ± 5% inhibition of the last pulse of the train (phasic inhibition) (n = 3 cells). Concentration-response curves for tonic and phasic block of hNav1.5 Na$^+$ currents by lidocaine (10–300 μM) and compound 4 (0.1–30 μM) were constructed (Fig. 3, b and d), and the corresponding pIC$_{50}$ values were calculated (Table 2). Using the present voltage clamp protocols, compound 4 was approximately 60-fold more potent than lidocaine and was strongly use-dependent, with a 30-fold shift in the potency for phasic block, relative to tonic. It is noteworthy that the use-dependent component of block reached steady state rapidly for each concentration of lidocaine tested, but for compound 4, true steady-state inhibition was not reached during the 200-pulse train (Fig. 3, a and c). This probably reflects the differences in the dissociation rates of the compounds (see below).

The characteristics of inhibition of neonatal rat tetrodotoxin-resistant Na$^+$ currents (Fig. 4), by lidocaine and compound 4, were very similar to those for inhibition of hNav1.5 Na$^+$ currents. Compound 4 exhibited strong use-dependent inhibition of rat tetrodotoxin-resistant Na$^+$ currents. At a concentration of 3 μM, there was minimal (~5%) tonic inhibition but 84 ± 4% inhibition of the last pulse of the train (phasic inhibition) (n = 3 cells) (Fig. 4, a and c, inset). The tonic and phasic pIC$_{50}$ values for inhibition of rat tetrodotoxin-resistant Na$^+$ currents by lidocaine and compound 4 were 3.8 and <4.5 (tonic) and 4.1 and 6.3 (phasic), respectively (n ≥ 3 cells). Similar data were obtained for inhibition of rNav1.2a Na$^+$ currents by lidocaine and compound 4 [pIC$_{50}$ values = <3.5 and <4.5 (tonic) and <3.5 and 6.0 (phasic), respectively (n ≥ 3 cells)].

In summary, under the present recording conditions, there was a small (~10-fold) difference between the tonic potencies of lidocaine and compound 4, compared with a 60- to 300-fold difference between the phasic potencies, at the three respective VGSC subtypes. Compound 4 was strongly use-dependent with a >30-fold difference between the tonic and phasic IC$_{50}$ values, compared with a <5-fold difference for lidocaine.

**TABLE 2**

<table>
<thead>
<tr>
<th>Compound</th>
<th>Tonic pIC$_{50}$</th>
<th>Phasic pIC$_{50}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lidocaine</td>
<td>3.5</td>
<td>4.2</td>
</tr>
<tr>
<td>Compound 2</td>
<td>3.9</td>
<td>4.9</td>
</tr>
<tr>
<td>Compound 3</td>
<td>4.2</td>
<td>5.4</td>
</tr>
<tr>
<td>Compound 4</td>
<td>4.5</td>
<td>6.0</td>
</tr>
<tr>
<td>Compound 5</td>
<td>4.6</td>
<td>5.8</td>
</tr>
<tr>
<td>Compound 6</td>
<td>4.9</td>
<td>5.8</td>
</tr>
<tr>
<td>Compound 7</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Compound 8</td>
<td>3.9</td>
<td>4.9</td>
</tr>
<tr>
<td>Compound 9</td>
<td>3.8</td>
<td>5.1</td>
</tr>
</tbody>
</table>

*a Compound disrupted gigaseal at 10 μM.

Fig. 3. Tonic and phasic inhibition of hNav1.5 Na$^+$ currents by lidocaine and compound 4. Normalized current responses in the presence of increasing concentrations of lidocaine (▲, 10 μM; ●, 30 μM; □, 100 μM; □, 300 μM) (a) and compound 4 (▲, 0.1 μM; ●, 0.3 μM; ●, 1 μM; □, 3 μM; ○, 10 μM; ○, 30 μM) (c). Na$^+$ current magnitude was monitored at a frequency of 0.2 Hz for 1 min. Cells were then exposed to lidocaine or compound 4 in the absence of depolarizing pulses for 3 min, followed by a 5-Hz train of 200 10-ms pulses from the holding potential (~120 mV) to the test potential (~20 mV), in the continuous presence of compound. Current amplitudes were normalized to the initial current in the absence of compound. Inset, representative current traces evoked by a single pulse in the absence of compound (control) and by pulses 1 and 200 of the train, in the presence of 300 μM lidocaine (a) or 3 μM compound 4 (epd 4, c). Concentration-response curves showing effect of lidocaine (b) and compound 4 (d) on the amplitude of the first (▲) and last (□) depolarizations in the 200-pulse train. Data represents mean ± S.E.M. of at least three cells. In a and c, the standard error bars have been omitted for clarity.
The rank order of potency of compound 4, for phasic inhibition of VGSC Na⁺ currents, was rat dorsal root ganglia tetrodotoxin-resistant Na⁺hNa1.2a = hNa1.5. However, the absolute difference in potency for inhibition of the three VGSC subtypes was ≤2-fold.

The tonic and phasic pIC₅₀ values for compounds 1 to 9 were determined on hNa1.5 Na⁺ currents (Table 2). There was a reasonable correlation (r² = 0.6, slope = 0.7, n = 8) between the phasic and FLIPR pIC₅₀ values for these compounds, supporting the conclusion that the potency of the dimers is dependent upon the length of the tether. Furthermore, the dimers each exhibited use-dependent block with a difference between the tonic and phasic IC₅₀ values of approximately 10-fold, or greater. The control compounds, 8 and 9, were both approximately 1 order of magnitude less potent than compound 4 for phasic block (Table 2). The kinetics of inhibition of hNa1.5 Na⁺ currents by compound 9 were similar to those of lidocaine such that inhibition of the current reached steady-state during the 200-pulse train (data not shown). In contrast, compound 8 had a profile similar to that of compound 4, and steady-state inhibition was not achieved during the 200-pulse train (data not shown). As noted previously, this probably reflects the differences in dissociation rates of the compounds. Unfortunately, it was not possible to assess the potency of compound 7 using voltage-clamp techniques, because at concentrations >10 µM, the compound disrupted the established giga-seal.

The Rate of Dissociation of Lidocaine Dimers from VGSCs Is Dependent upon the Length of the Tether. hNa1.5–293-EBNA cells were exposed to equieffective (approximately phasic IC₅₀) concentrations (in parentheses) of lidocaine (300 µM), compound 2 (30 µM), compound 3 (10 µM), compound 4 (3 µM), compound 5 (10 µM), compound 6 (10 µM), compound 8 (30 µM) or compound 9 (30 µM), and the rates of recovery from inhibition were determined as described under Materials and Methods. The effect of lidocaine was rapidly (τ < 10 s) reversible upon washout (Fig. 5a). In contrast, the dimers exhibited slower, linker length-dependent dissociation rates with τ values of 133 s, 3000 s, 41 s, and 50 s for compounds 2, 3, 5, and 6, respectively (Fig. 5a). There was negligible recovery of the hNa1.5 Na⁺ current from inhibition by compound 4 up to 10 min after washout (Fig. 5a). It was not possible to investigate longer washout periods because of instability in the recordings at later time points, and a τ value was not determined. Therefore, the rank order for dissociation from hNa1.5 VGSCs was lidocaine > compound 5 = compound 6 > compound 2 > compound 3 > compound 4. The dissociation of compound 4 was not enhanced by changing the holding potential to a more negative potential (~140 mV), during the washout period (data not shown). In contrast to compound 4, dissociation of both the controls, compounds 8 and 9, could be observed. Thus, compound 9 had a rapid dissociation rate (τ < 10 s) similar to that of lidocaine, whereas compound 8 had a comparatively slower dissociation rate with a τ value of 233 s.

VGSC subtypes was described under Materials and Methods. The presence of 300 µM lidocaine (a) or 3 µM compound 4 (b) in the absence of depolarizing pulses for 3 min, followed by a 5-Hz train of 200 10-ms pulses from the holding potential (~90 mV) to the test potential (~0 mV), in the continuous presence of compound. Current amplitudes were normalized to the initial current in the absence of compound and then corrected for current run down, as described under Materials and Methods. Inset, representative current traces evoked by a single pulse in the absence of compound (control) and by 10 µM lidocaine (a) or 3 µM compound 4 (c) in the absence of depolarizing pulses. Data represents mean ± S.E.M. of at least three cells. In a and c, the standard error bars have been omitted for clarity.
compounds 3 and 4 the rates were slower with \( \tau \) values of 197 s and 335 s, respectively.

**Monomeric VGSC Inhibitors Attenuate Compound 4-Mediated Inhibition of hNaV1.5 VGSCs.** To investigate the relationship between the well characterized local anesthetic binding site and the compound 4 binding site(s) on VGSCs, we investigated the effect of coincubation with local anesthetic receptor site inhibitors, or tetrodotoxin, on compound 4-mediated inhibition of hNaV1.5 \( \mathrm{Na}^+ \) currents. hNaV1.5–293-EBNA cells were incubated with compound 4 in the absence or presence of a local anesthetic or tetrodotoxin, as described under Materials and Methods. At the end of the stimulus train, the compounds were washed out, and current magnitude was monitored at a frequency of 0.2 Hz for a further 10 min.

Compound 4 (1 \( \mu \)M) produced 44 \( \pm \) 7\% (\( n = 3 \) cells) inhibition of hNaV1.5 \( \mathrm{Na}^+ \) currents, which was maintained up to 10 min after washout (Fig. 6a, control), consistent with those data described in the previous section. In contrast, after coincubation with mexiletine (1 mM), but not tetrodotoxin (100 \( \mu \)M), negligible compound 4-mediated inhibition was apparent after washout (Fig. 6a). Application of mexiletine (1 mM) alone or tetrodotoxin (100 \( \mu \)M) alone produced complete inhibition of hNaV1.5 \( \mathrm{Na}^+ \) currents, which recovered to pre-drug amplitudes within 10 s of inhibitor washout (\( n = 3 \) cells, data not shown). In subsequent experiments, hNaV1.5–293-EBNA cells were incubated with increasing concentrations of compound 4, in the absence or presence of a fixed concentration of mexiletine and concentration-response curves of normalized current amplitude (at 10 min after compound washout) constructed. Coincubation with mexiletine (0.3 or 1 mM) produced parallel, rightward shifts in the compound 4 concentration-response curve (Fig. 6b). The corresponding Hill coefficients for compound 4 were 1.2, 1.1, and 1.3 in the absence and presence of 0.3 and 1 mM mexiletine, respectively. Similar experiments were conducted using lidocaine (1 mM), bupivacaine (1 mM), and pimozone (0.01 mM) (data not shown). The respective pIC \(_{50}\) values for phasic inhibition were calculated and then, using the Schild equation (Arunlakshana and Schild, 1959), the apparent \( pK_a \) values for the different VGSC inhibitors were determined (Table 3). There was a good correspondence between the \( pK_a \) values and the respective phasic pIC \(_{50}\) values at hNaV1.5 (Table 2).

**Monomeric VGSC Inhibitors Increase the Rate of Dissociation of Compound 4 from hNaV1.5 VGSCs.** The observation that coincubation with local anesthetic receptor site inhibitors attenuated interaction of compound 4 with hNaV1.5 VGSCs is consistent with competitive antagonism.
However, a strong negative allosteric interaction between local anesthetic receptor site inhibitors and compound 4 cannot be ruled out. To examine further the relationship between the compound 4 binding-site(s) and the local anesthetic binding site, the influence of free VGSC inhibitors on the dissociation of compound 4 from hNa1.5 VGSCs was studied.

hNa1.5–293-EBNA cells were incubated with compound 4 (10 μM), as described under Materials and Methods, to elicit maximal occupancy of the hNa1.5 VGSCs. At the end of the stimulus train, compound 4 was washed out and replaced with a monomeric VGSC inhibitor for a specified time (“chase period”) or with a drug-free extracellular buffer (control). Current magnitude was monitored (at a frequency of 0.2 Hz) throughout the duration of the inhibitor application and, for an additional 5-min washout period, with drug-free extracellular buffer.

Under control conditions, compound 4 (10 μM) produced 94 ± 2% (n = 3 cells) inhibition of hNa1.5 Na+ currents, which was maintained up to 10 min after washout of the compound (Figs. 7, a and c, control). However, after chase (5 min) with increasing concentrations of lidocaine, there was a significant increase in the magnitude of the residual Na+ current, determined 5 min after washout of lidocaine (Fig. 7a) (one-way ANOVA, p < 0.0001; Dunnett’s t test, p > 0.05, p < 0.05, p < 0.01, p < 0.01 for 0.3, 1.0, 3.0, and 10 mM lidocaine, respectively). Similar results were obtained with increasing concentrations of mexiletine (Fig. 7c) (one-way ANOVA, p < 0.0001; Dunnett’s t test, p > 0.05, p > 0.05, p < 0.01, p < 0.01 for 0.1, 0.3, 1.0, and 3.0 mM mexiletine, respectively). Together, these data suggest that both lidocaine and mexiletine produced a concentration-dependent increase in the rate of dissociation of compound 4 from hNa1.5 VGSCs. Consistent with the hypothesis that monomeric inhibitors increased the rate of dissociation of compound 4, a time-dependent increase in the magnitude of the residual Na+ current (determined at 5 min after washout of the inhibitor) was observed after chase (1, 5, or 10 min) with a fixed concentration of lidocaine (3 mM) or mexiletine (10 mM) (Fig. 7, b and d).

Alternate local anesthetic (bupivacaine) or anticonvulsant (lamotrigine, 4030W92) VGSC inhibitors also accelerated the dissociation of compound 4. Thus, after a 5-min chase with a 1 mM concentration of the respective inhibitors, and a subsequent 5-min washout period, at least 40% recovery of the hNa1.5 Na+ currents was observed (Table 4). In contrast, the pore-blocking toxin tetrodotoxin (100 μM) had no significant effect on compound 4 dissociation (p > 0.38, unpaired student’s t test). There was a poor correlation between the tonic and phasic potency values of the inhibitors and their ability to accelerate dissociation of compound 4 (Table 4). Thus, at a concentration of 1 mM, 4030W92 promoted the

### TABLE 4
Effect of free local anesthetic, antiarrhythmic, or anticonvulsant VGSC inhibitors on the dissociation of compound 4 from hNa1.5 VGSCs. hNa1.5–293-EBNA cells were incubated with compound 4 (10 μM) according to the standard protocol described under Materials and Methods, to elicit full occupancy of the hNa1.5 VGSCs. At the end of the stimulus train, compound 4 was washed out and replaced with VGSC inhibitor (at the concentrations specified), or drug-free extracellular buffer (control), for a 5-min chase period. Current magnitude was monitored (at a frequency of 0.2 Hz) throughout the duration of the inhibitor application and an additional 5-min washout period, with drug-free extracellular buffer. Compounds were applied for the period(s) indicated by the black bar. Data represents mean ± S.E.M. of at least three cells.

<table>
<thead>
<tr>
<th>VGSC Inhibitor</th>
<th>hNa1.5 IC50 Tonic</th>
<th>Chace Concentration</th>
<th>Recovery of Na+ Current</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>μM</td>
<td>mM</td>
<td>%</td>
</tr>
<tr>
<td>Control</td>
<td>N.A.</td>
<td>N.A.</td>
<td>6 ± 2</td>
</tr>
<tr>
<td>Lidocaine</td>
<td>292</td>
<td>57</td>
<td>3</td>
</tr>
<tr>
<td>Mexiletine</td>
<td>168</td>
<td>59</td>
<td>1</td>
</tr>
<tr>
<td>Bupivacaine</td>
<td>84</td>
<td>12</td>
<td>1</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>185</td>
<td>144</td>
<td>1</td>
</tr>
<tr>
<td>4030W92</td>
<td>&gt;300</td>
<td>296</td>
<td>1</td>
</tr>
</tbody>
</table>

N.A., not applicable.
greatest degree of recovery (67 ± 5%, n = 3) of hNa1,1.5 Na+ currents, although this compound exhibited the lowest tonic and phasic potency values (Table 4).

Similar experiments conducted using rNa1,2a-CHO cells demonstrated that mexiletine also accelerated the dissociation of compound 4 from rNa1,2a VGSCs. As described above, in contrast to hNa1,1.5, dissociation of compound 4 from rNa1,2a could be observed in the absence of an inhibitor. Thus, under control conditions, at 10 min after washout of compound 4 (10 μM), the residual current was 77 ± 6% (n = 3 cells) of the initial current amplitude. In contrast, after a 5-min chase with 1 mM mexiletine, and a subsequent 5 min washout period, there was a significant increase in the residual current (112 ± 7%, n = 3 cells; p = 0.02, unpaired t test).

Discussion

The present study has demonstrated that N-linked lidocaine dimers, in which the lidocaine moieties are linked by an unsubstituted alkylene chain, are potent, use-dependent inhibitors of rNa1,2a, hNa1,1.5, and rNa1,1.8 VGSCs. The potency and dissociation rate of the dimers was dependent upon the length of the linker coupling the two lidocaine moieties. The n-butylene-linked dimer (compound 4) was the most potent and exhibited the slowest dissociation rate.

The observation that varying the length of the linker modulated both the potency and dissociation rate of the dimers is consistent with a multivalent interaction at VGSCs (Mammen et al., 1998; Kiessling et al., 2000; Wright and Usher, 2001). A linker length-dependent increase in potency of dimeric ligands relative to the monomer has been reported for compounds interacting with cyclic nucleotide-gated (Kramer and Karpen, 1998), SKCa (Galanakis et al., 1996), and nicotinic acetylcholine receptor (Rosini et al., 1999) channels. Polymer-linked cGMP dimers simultaneously occupy two binding sites on the cyclic nucleotide-gated channel. The potency and the dissociation rate of these dimers are dependent upon the length of the linker joining the two cGMP moieties, similar to the present findings. However, in contrast to cyclic nucleotide-gated channels, which are homotetramers with a cGMP binding site on each subunit, the presence of two or more distinct binding sites for local anesthetics on VGSCs has yet to be confirmed.

Additional support for a multivalent interaction comes from studies using control compounds. Thus, compound 7, which retains the amine but lacks the amide and arene motifs of the second lidocaine moiety, had low affinity (pIC50 < 4) for VGSCs. Furthermore, compound 8, which retains the amine and amide but lacks the arene motif, and compound 9, which retains the arene but lacks the corresponding amine motif, although more potent VGSC inhibitors than lidocaine, were at least 10-fold less potent than compound 4 and exhibited significantly faster dissociation rates. These data suggest that the presence of a second, intact local anesthetic pharmacophore was critical to manifest the dramatic increase in potency (relative to lidocaine) and slow dissociation rate of compound 4.

The correlation between hydrophobicity and the in vitro and in vivo efficacy of VGSC blockers is well established (Strichartz et al., 1990). In the present study, however, the most hydrophobic molecules [i.e., compounds 5 and 6 (the relative increase in logD value being ~ 0.5 per methylene unit)] had lower in vitro potencies and exhibited significantly faster dissociation rates from VGSCs than compounds 3 or 4. Differences in local anesthetic pKa values and hence the relative proportions of cationic and uncharged free amine forms, also can influence the extent and/or kinetics of inhibition of VGSCs (Chernoff and Strichartz, 1990). The calculated pKa value (Pallas; CompuDrug International, Inc., Sedona, AZ) for lidocaine is 8.03. In comparison, for the dimers, the calculated pKa values for the amine in the first lidocaine moiety range from 6.83 (compound 2) to 8.23 (compounds 5 and 6) and in the second moiety from 3.79 (compound 2) to 7.62 (compounds 5 and 6). It is therefore, possible that, except for compounds 5 and 6, which are diprotonated, all the dimers exist as monoprotonated, or even uncharged (i.e., compound 2) species at physiological pH. The observation that compound 8, which has calculated pKa values (7.69, 6.67) very similar to those of compound 4 (7.37, 6.37), yet exhibited lower potency and a more rapid dissociation rate, is consistent with the proposal that differences in charge state alone are unlikely to account for the dramatic increase in potency and/or kinetic properties of compound 4. To summarize, it is proposed that the specific structure of compound 4 (as discussed above), and not simply its physical properties (i.e., hydrophobicity, charge state), accounts for the slow dissociation and enhanced potency at VGSCs.

The strongest evidence for a bivalent interaction of a lidocaine dimer with VGSCs derives from the observation that free local anesthetics increase the dissociation of compound 4 from hNa1,1.5 and rNa1,2a. In monovalent binding, the dissociation of a ligand from its binding site is determined by the rate constant for dissociation and is unaffected by the concentration of a competing free ligand in solution. However, in bivalent binding, dissociation occurs in stages, and its rate can be accelerated by occupancy of either site by monovalent

![Diagram](https://example.com/diagram.png)
ligand (Fig. 8; Kramer and Karpen, 1998). One interpretation of the present findings is that compound 4 binds to the conserved local anesthetic receptor and a second site. The binding of compound 4 to hNa,1,5 VGSCs was inhibited, in an apparently competitive manner, by coinubcation with local anesthetic, anticonvulsant, or antiarrhythmic agents, with estimated pKd values similar to their corresponding phasic IC50 values. These data are consistent with the hypothesis that one of the binding sites for compound 4 is the conserved local anesthetic receptor. Free monovalent local anesthetics could accelerate dissociation of compound 4 through occupancy of this site. However, the apparent lack of correlation between the ability of such ligands to enhance the dissociation rate of compound 4 and their affinities for the conserved local anesthetic site suggests instead that these monovalent ligands have some affinity for the second site, and it is through interaction at this site that they promote dissociation of compound 4 (Fig. 8).

The lidocaine dimers may span adjacent domains in the VGSC or, alternatively, bind to vicinal binding sites in the protein, as has been proposed for dequalinium binding to SKCa channels (Galanakis et al., 1996). A low-resolution (19 Å) three-dimensional structure of the VGSC has revealed a pseudotetrameric arrangement of the channel (Sato et al., 2001). Furthermore, as discussed previously, various amino acid residues in transmembrane region S6 from domains 1, 3, and 4 have been shown to be important for local anesthetic binding to VGSCs. However, it is believed that this reflects a domain interface binding site in which individual amino acid residues from the different S6 regions make binding interactions with the inhibitor, rather than the presence of independent binding sites (Catterall, 2002). Nevertheless, several groups have suggested the presence of additional binding sites for local anesthetics on VGSCs. The presence of two binding sites was proposed as one explanation for the influence of Na+ channel activators on stereoselective inhibition by bupivacaine and other local anesthetics (Lee-Son et al., 1992). More recently, the presence of one or more additional binding sites, which are unmasked upon channel activation, has been proposed for both lidocaine (Leuver et al., 2004) and prenylamine (Mujtaba et al., 2001). Indeed, voltage-clamp and site-directed mutagenesis techniques suggest that prenylamine and bupivacaine act at separate pharmacological receptors on hNa,1.5 (Mujtaba et al., 2002). Finally, interactions between lidocaine and structural regions of hNa,1.5 (Bennett et al., 1995) or rNa,1.2a (Kuroda et al., 1996, 2000), which are responsible for inactivation, have been reported.

The present findings of a small (∼10-fold) difference between the tonic potencies of lidocaine and compound 4, compared with the dramatic (60- to 300-fold) difference between the phasic potencies, suggests that conformational changes in VGSCs, upon depolarization, expose an additional binding site and/or binding interaction(s) for the second lidocaine moiety, and the resultant multivalent interaction underlies the enhanced phasic potency and slow dissociation rate of compound 4. One advantage of multivalent ligands is that, in addition to an increase in potency, such compounds may exhibit increased selectivity as a result of bridging between proximal binding sites that have alternate structure and/or spatial localization on target proteins (Wright and Usher, 2001). In the present study, although the dimers exhibited significant increases in potency relative to lidocaine, they did not exhibit significant subtype selectivity, suggesting that the identity, orientation, and/or distance between the relevant binding sites must be similar for the three VGSCs. This may not be surprising because the nine sodium channel isoforms (Na,1.1-Na,1.9) are more than 50% identical in amino acid sequence in the extracellular and transmembrane domains (Goldin et al., 2000). Furthermore, in the putative local anesthetic binding site in D4S6, the critical phenylalanine and tyrosine residues (Catterall, 2002) are conserved among Na,1.2a, Na,1.5, and Na,1.8. However, there were significant differences in the rates of dissociation of the dimers from rNa,1.2a and hNa,1.5 that may reflect subtle differences in the interaction with these channels.

In summary, these studies have demonstrated that N-linked lidocaine dimers, tethered by unsubstituted alkylene linkers of varying length, are potent, use-dependent VGSC inhibitors. Both the potency and dissociation rate of the dimers was dependent upon the length of the linker coupling the two lidocaine moieties, consistent with a multivalent interaction. Furthermore, the present data suggest that a four-carbon alkylene chain provides the optimal three-dimensional orientation for binding within the series, with both lidocaine moieties in compound 4 making specific contacts with the VGSC. The observation that monomeric VGSC inhibitors accelerate the dissociation of compound 4 supports the hypothesis that compound 4 simultaneously occupies two binding sites on VGSCs. Both sites can be bound by local anesthetic, anticonvulsant, or antiarrhythmic agents, one being the conventional local anesthetic site and the other an as-yet-undefined site.

Acknowledgments

We thank Mathai Mammen for helpful discussion during the preparation of the manuscript.

References

Hockerman GH, Johnson BD, Abbott MR, Scheuer T, and Catterall WA (1997) Molecular determinants of high affinity phenylalkylamine block of L-type calcium


**Address correspondence to:** Jacqueline Smith, Theravance Inc., 901 Gateway Blvd., South San Francisco, CA 94080. E-mail: jsmith@theravance.com